Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profile of either Dead neuron+/Fcrls+/CD11b+/Ly6C- or Dead neuron-/Fcrls+/CD11b+/Ly6C- microglia from the brain I

ABSTRACT: We used bulk RNA sequencing to investigate the molecular signature of phagocytic and non-phagocytic microglia affected by APOE isoform (APOE3-KI vs. APOE4-KI)

ORGANISM(S): Mus musculus

PROVIDER: GSE234348 | GEO | 2023/07/31

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Gene expression profile of either Dead neuron+/Fcrls+/CD11b+/Ly6C- or Dead neuron-/Fcrls+/CD11b+/Ly6C- microglia from the brain II

Project description:We used bulk RNA sequencing to investigate the molecular signature of phagocytic and non-phagocytic microglia affected by APOE isoform (APOE3-KI vs. APOE3-cKO vs. APOE4-KI vs. APOE4-cKO)

2023-07-31 | GSE234350 | GEO

Gene expression profile of Fcrls+/CD11b+/Ly6C- microglia from the brain II

Project description:We used bulk RNA sequencing to investigate the molecular signature of microglia affected by microglia-specific APOE isoform (APOE3 vs. APOE4) in both WT and P301S mice

2023-07-31 | GSE234391 | GEO

Gene expression profile of either Dead neuron+/Fcrls+/CD11b+/Ly6C- or Dead neuron-/Fcrls+/CD11b+/Ly6C- microglia from the brain

Project description:We used bulk RNA sequencing to investigate the molecular signature of both phagocytic microglia and non-phagocytic microglia affected by deletion of Itgb8 in microglia.

2023-07-31 | GSE234502 | GEO

Gene expression profile of Dead neuron+/Fcrls+/CD11b+/Ly6C- microglia from the brain

Project description:We used bulk RNA sequencing to investigate the molecular signature of phagocytic microglia affected by deletion of Spi1 in microglia.

2023-07-31 | GSE234380 | GEO

Gene expression profile of Fcrls+/CD11b+/Ly6C- microglia from the brain I

Project description:We used bulk RNA sequencing to investigate the molecular signature of microglia affected by PU.1 inhibitor in APP/PS1:APOE4-KI mice.

2023-07-31 | GSE234383 | GEO

Differential gene expression in APOE3 and APOE4 gene targeted replacement mice

Project description:The aim of the study was to investigate hepatic gene expression profiles differentially regulated by the APOE genotype in gene targeted replacement mice. The APOE4 genotype is associated with increased mortality in the elderly and is an independent risk factor for age-dependent chronic diseases. However, little is known about the underlying mechanisms and molecular targets involved in the APOE4-risk association. As APOE is centrally involved in lipid and cholesterol metabolism and in large part is produced in the liver, we analyzed hepatic RNA profiles of APOE4- and APOE3-expressing mice. 2 groups of 5 animals with 1 liver extract per animal. Mice were homozygous for a human APOE3 or APOE4 gene targeted replacement of the endogenous mouse Apoe gene (B6.129P2-Apoetm2(APOE*3)Mae N8 or B6.129P2-Apoetm3(APOE*4)Mae N8, Taconic Transgenic ModelsM-bM-^DM-", http://www.taconic.com/wmspage.cfm?parm1=2542), purchased at the age of 6-8 weeks, strain C57BL/6, 3 months old at the performance of the microarray, 6 weeks on a high-fat diet containing 41% energy from milk fat and 2 g/kg cholesterol.

2012-12-15 | E-GEOD-42930 | biostudies-arrayexpress

Epigenetic profile of Fcrls+/CD11b+/Ly6C- microglia from the brain

Project description:Determine the histone modification of microglia expressing different human APOE variants.

2023-07-31 | GSE234358 | GEO

Gene expression profile of Fcrls+/CD11b+/Ly6C- microglia from the brain V

Project description:We used bulk RNA sequencing to investigate the molecular signature of microglia affected by deletion of microglial APOE4 in APP/PS1 mice.

2023-07-31 | GSE235630 | GEO

Peripherally-expressed apoE4 impairs brain functions and exacerbates amyloid pathogenesis by compromising cerebrovascular functions

Project description:The apolipoprotein E4 (APOE4) gene is the strongest genetic risk factor for late-onset Alzheimer’s disease (AD). ApoE is a lipid carrier abundantly expressed in both brain and periphery. As peripheral apoE is separated from brain apoE by the blood-brain barrier, it remains unclear whether peripheral apoE impacts brain functions and AD pathogenesis. To investigate this, we developed novel mouse models that conditionally express human APOE3 or APOE4 only in the liver with no detectable apoE in the brain. We found that liver-expressed apoE4 compromised synaptic plasticity and cognitive behaviors likely by impairing cerebrovascular functions. Remarkably, liver-expressed apoE4 exacerbated brain amyloid pathology, whereas apoE3 reduced it. Our findings demonstrate a pathogenic effect of peripheral apoE4, providing strong rationale for targeting peripheral apoE to treat AD.

2022-06-15 | GSE125501 | GEO

Domino-like Effect of C112R Mutation on APOE4 Aggregation and Its Suppression by Alzheimer’s Disease Drug Candidate

Project description:The development of treatment for Alzheimer’s Disease (AD) is hindered by a limited understanding of its structural basis. Apolipoprotein E (APOE) ε4 genotype is the most important risk factor for late-onset AD. APOE4 differs from the APOE3 isoform by a single mutation, C112R. Here, we employ crystallography, biophysical methods and computer simulations to dissect the “domino-like” effect of C112R substitution on APOE4 behaviour. We found that the mutation induces long-distance (>15 Å) conformational changes leading to geometrically distinct T-shaped dimeric unit of APOE4 compared to APOE3. By mutagenesis, we demonstrate that the APOE4 unit is more prone to aggregation than that of the APOE3. AD drug candidate tramiprosate and metabolite 3-sulfopropanoic acid induce APOE3-like conformational behaviour in APOE4 and suppress its aggregation propensity. Omics analysis of APOE ε4/ε4 cerebral organoids treated with tramiprosate revealed its effect on cholesteryl esters, the storage product of excess cholesterol. Our results connect the APOE4 structure with its aggregation propensity, which can be further exploited in drug development for neurodegeneration and ageing.

2023-07-20 | PXD036416 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data